Join MySLAS Social

A Perspective on Extreme Open Science: Companies Sharing Compounds without Restriction

Read this Issue

Timothy M. Willson, Ph.D.
Research Professor
Chief Scientist, SGC-UNC
University of North Carolina Eshelman School of Pharmacy
Chapel Hill, NC USA

Timothy M. Willson is a research professor at the University of North Carolina (UNC) Eshelman School of Pharmacy in Chapel Hill, NC, and chief scientific officer for the United States site of the Structural Genomics Consortium (SGC). He trained as an organic chemist before embarking on a 25-year career as a medicinal chemist in the pharmaceutical industry. In 2015, he moved to UNC to pursue his passion to apply open science to drug discovery.

A unifying theme of Willson’s research has been the use of chemistry to illuminate human biology. He developed chemical probes to deorphanize the nuclear receptors PPARa, PPARg, LXR, FXR, CAR and PXR that supported research across the global scientific community into their role in human diseases and drug metabolism. A direct result of his research was the discovery of the FXR agonist obeticholic acid, which was approved as a drug for the treatment of primary biliary cholangitis.

Willson’s current research focus at the SGC is the development and distribution of a chemogenomic set of small molecule kinase inhibitors (KCGS) that can be used to study the biology of hundreds of understudied ‘dark’ kinases.

Structural Genomics Consortium
UNC Eshelman School of Pharmacy

SLAS Publications
Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell Growth

SLAS publishes two PubMed:MEDLINE-indexed journals and accepts manuscripts on an ongoing basis from members and non-members.  > READ MORE

May 20, 2019